Tolvaptan for Fluid Management in Living Donor Liver Transplant Recipients

被引:0
作者
Imai, Shunichi [1 ]
Shinoda, Masahiro [1 ]
Obara, Hideaki [1 ]
Kitago, Minoru [1 ]
Hibi, Taizo [1 ]
Abe, Yuta [1 ]
Yagi, Hiroshi [1 ]
Matsubara, Kentaro [1 ]
Higashi, Hisanobu [1 ]
Itano, Osamu [1 ]
Kitagawa, Yuko [1 ]
机构
[1] Keio Univ, Sch Med, Dept Surg, Tokyo, Japan
关键词
Diuretics; Liver Transplantation; Living Donors; Postoperative Care; ATRIAL-NATRIURETIC-PEPTIDE; HEART-FAILURE; CONTROLLED-TRIAL; KIDNEY INJURY; HEPATIC EDEMA; ANTAGONIST; CIRRHOSIS; EFFICACY; PHASE;
D O I
10.12659/AOT.905817
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: Tolvaptan, an antagonist of the vasopressin V2 receptor is a novel oral diuretic that promotes water excretion selectively. We have used furosemide as a primary diuretic and added human atrial natriuretic peptide (hANP) if necessary for fluid management postoperatively in living-donor liver transplantation (LDLT) recipients. Recently we introduced tolvaptan and used both tolvaptan and furosemide as primary diuretics. Material/Methods: Clinical outcomes were compared between LDLT recipients whose postoperative fluid management was performed before (control group, n=10) and after (tolvaptan group, n=16) introduction of tolvaptan. Results: Preoperative and intraoperative demographic data did not differ significantly between the groups except for the period of post-surgical follow-up and total ischemic time. Urine volume was 1,242 +/- 692, 2,240 +/- 1307, and 2,268 +/- 1262 mL on postoperative day 1, 3, and 7, respectively, in the tolvaptan group. These volumes did not significantly differ from those in control group (1,027 +/- 462, 1,788 +/- 909, and 2,057 +/- 1216 mL on day 1, 3, and 7 postoperatively, respectively). Body weight gain and fluid volume from abdominal drainage tubes postoperatively did not differ significantly between groups. The time from hANP initiation to discontinuation and the time to removal of central vein catheters were significantly reduced in tolvaptan-treated patients. No severe side effects directly related to tolvaptan were observed. The survival rate at month 6 was 90.0% in control patients versus 93.8% in tolvaptan-treated patients. Conclusions: The outcomes of this investigation indicate that tolvaptan in combination with furosemide provides an adequate diuretic for fluid management subsequent to LDLT without causing adverse effects.
引用
收藏
页码:25 / 33
页数:9
相关论文
共 50 条
  • [41] The care of donors and recipients in adult living donor liver transplantation
    Hendrickse, A.
    Ko, J.
    Sakai, T.
    BJA EDUCATION, 2022, 22 (10) : 387 - 395
  • [42] Hepatitis C Disease Severity in Living Versus Deceased Donor Liver Transplant Recipients: An Extended Observation Study
    Terrault, Norah A.
    Stravitz, R. Todd
    Lok, Anna S. F.
    Everson, Greg T.
    Brown, Robert S., Jr.
    Kulik, Laura M.
    Olthoff, Kim M.
    Saab, Sammy
    Adeyi, Ovedele
    Argo, Curtis K.
    Everhart, Jay E.
    Rodrigo, Del R.
    HEPATOLOGY, 2014, 59 (04) : 1311 - 1319
  • [43] Significance of Proper Graft Selection in Adult Living-Donor Liver Transplant Recipients with Preoperative Deteriorated Condition
    Iida, Taku
    Masuda, Koji
    Matsuyama, Takehisa
    Harada, Shunpei
    Nakamura, Tsukasa
    Koshino, Katsuhiro
    Suzuki, Tomoyuki
    Nobori, Shuji
    Ushigome, Hidetaka
    Ito, Takashi
    Sakamoto, Seisuke
    Uryuhara, Kenji
    Okajima, Hideaki
    Kaihara, Satoshi
    Uemoto, Shinji
    Yoshimura, Norio
    ANNALS OF TRANSPLANTATION, 2017, 22 : 541 - 549
  • [44] Neurological Complications in Recipients after Living Donor Liver Transplantation
    Khalil, Mohamed
    Elbanhawy, Iman
    Elsherbiny, Ashraf
    Amer, Hanan
    Ahmed, Sandra
    NEUROLOGY INDIA, 2020, 68 (01) : 146 - 151
  • [45] Biliary complications in recipients of living-donor liver transplantation
    Takatsuki, Mitsuhisa
    Eguchi, Susumu
    Kawashita, Yujo
    Kanematsu, Takashi
    JOURNAL OF HEPATO-BILIARY-PANCREATIC SURGERY, 2006, 13 (06): : 497 - 501
  • [46] Living donor liver transplantation. Selection of liver donors and recipients; results
    Braun, F.
    Gerken, G.
    Broering, D. C.
    GASTROENTEROLOGE, 2009, 4 (06): : 516 - 525
  • [47] Impact of MRCP findings on the management of biliary strictures in post-living donor liver transplant
    Abdelgawad, Mohamed Saied
    Aly, Rasha Abdelhafiz
    Sherif, Ahmed Elshawadfy
    EGYPTIAN JOURNAL OF RADIOLOGY AND NUCLEAR MEDICINE, 2019, 50 (01)
  • [48] Impact of MRCP findings on the management of biliary strictures in post-living donor liver transplant
    Mohamed Saied Abdelgawad
    Rasha Abdelhafiz Aly
    Ahmed Elshawadfy Sherif
    Egyptian Journal of Radiology and Nuclear Medicine, 50
  • [49] Experience with artificial liver support in 16 living related liver transplant recipients
    Kawagishi, N
    Ohkohchi, N
    Fujimori, K
    Orii, T
    Koyamada, N
    Kikuchi, H
    Satomi, S
    THERAPEUTIC APHERESIS, 2001, 5 (01): : 7 - 11
  • [50] Does donor muscularity "pump up" living donor liver transplant survival?
    Cullen, Jonathan Michael
    Goldaracena, Nicolas
    AMERICAN JOURNAL OF TRANSPLANTATION, 2020, 20 (12) : 3281 - 3282